Fulcrum Therapeutics to Participate in Upcoming September Conferences

CAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.^® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a series of investor meetings at the following conferences:

• Wells Fargo Healthcare Conference
  Wednesday, September 4, 2024
  Boston, MA

• Morgan Stanley 22^nd Annual Global Healthcare Conference
  Friday, September 6, 2024
  New York, NY

About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.

Contact:
Chris Calabrese
LifeSci Advisors, LLC
[email protected]
917-680-5608

You May Also Be Interested In

• Steelworkers back Canada holding the line on trade, call for a stronger response to protect Canadian jobs and industry
• Memecoin AI Agent Trading 2026: How MemeToro Could Redefine Automated Crypto Launches
• The Apex Institute Reveals What Hiring Managers Actually Want in Cloud and AI Infrastructure Roles